Lupin is in focus following a Jefferies note that said the company's market share in albuterol HFA inhaler has dropped. The global brokerage said that Lupin’s market share is down 50 percent month-on-month (MoM). The market share for the past four weeks has come in at around 3.3 percent.

The development comes days after in its Q3 conference call, Lupin had indicated that they are looking to increase market share in albuterol to around 20 percent.

The management said that there is a temporary lull owing to some irregular raw materials.

“We remain confident of our albuterol market share and expect it to ramp-up in line with what we have indicated earlier. The product has been consistently improving its markets share. There has been a temporary lull owing to some irregular raw material coming in from foreign suppliers in Europe due to COVID. But we expect the issue to iron out in the next few days and sales to resume to previous highs. This would be evident even during the course of the quarter,” Ramesh Swaminathan, ED and CFO of Lupin told CNBC-TV18.

Watch the video for more

(Edited by : Ajay Vaishnav)